Brief: Enliven Therapeutics Announces Positive Proof Of Concept Data From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia
11/04/2024 15:35
April 11 (Reuters) - Enliven Therapeutics Inc ELVN.O :
* ENLIVEN THERAPEUTICS ANNOUNCES POSITIVE PROOF OF CONCEPT
DATA
FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CHRONIC MYELOID
LEUKEMIA
* ENLIVEN THERAPEUTICS INC: ELVN-001 WAS WELL TOLERATED WITH
NO ≥
GRADE 3 TREATMENT-RELATED NON-HEMATOLOGIC TOXICITIES REPORTED
Source text for Eikon: ID:nGNX7QTC89
Further company coverage: ELVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enliven Therapeutics
See all newsBrief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses